Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Autor: Barbui T; Division of Hematology, Ospedale Giovanni XXIII, Bergamo, Italy., Tefferi A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Vannucchi AM; CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy., Passamonti F; Division of Hematology, Department of Medicine and Surgery, Ospedale di Circolo, University of Insubria, ASST Sette Laghi, Varese, Italy., Silver RT; Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA., Hoffman R; Tisch Cancer Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA., Verstovsek S; Department of Leukemia, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA., Mesa R; UT Health San Antonio Cancer Center, San Antonio, TX, USA., Kiladjian JJ; Centre d'Investigations Cliniques (CIC 1427), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, INSERM, Université Paris 7, Paris, France., Hehlmann R; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Reiter A; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Cervantes F; Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain., Harrison C; Department of Hematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK., Mc Mullin MF; Centre for Medical Education, Queen's University, Belfast, UK., Hasselbalch HC; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Koschmieder S; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany., Marchetti M; Hematology Day Service, Oncology SOC, Hospital Cardinal Massaia, Asti, Italy., Bacigalupo A; Istituto di Ematologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, Italy., Finazzi G; Division of Hematology, Ospedale Giovanni XXIII, Bergamo, Italy., Kroeger N; Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Griesshammer M; Department of Hematology and Oncology, Johannes Wesling Medical Centre Minden, Academic Hospital of the University of Hannover, Minden, Germany., Birgegard G; Department of Hematology, Uppsala University, Uppsala, Sweden., Barosi G; Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy. barosig@smatteo.pv.it.

Publikováno v: Leukemia [Leukemia] 2018 May; Vol. 32 (5), pp. 1057-1069. Date of Electronic Publication: 2018 Feb 27.

RBC-transfusion guidelines update.

Autor: Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S

Publikováno v: Leukemia research [Leuk Res] 2012 May; Vol. 36 (5), pp. 659-60. Date of Electronic Publication: 2012 Feb 14.

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.

Autor: Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T

Publikováno v: British journal of haematology [Br J Haematol] 2010 Mar; Vol. 148 (6), pp. 961-3. Date of Electronic Publication: 2009 Nov 23.